BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $53
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $47 to $53.
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $47 to $53.